Literature DB >> 1035506

Rapid analytic method for adriamycin and metabolites in human plasma by a thin-film fluorescence scanner.

E Watson, K K Chan.   

Abstract

A rapid and highly sensitive method is described for the quantitative determination of adriamycin and metabolites in plasma. Adriamycin (Ad) with daunorubicin added as the internal standard was extracted from plasma with chloroform-isopropanol (1:1), separated by thin-layer chromatography (TLC), and quantitated in situ via a fluorescence scanning technique. This method represents one of the very few reliable quantitative TLC methods and is suitable for the routine determination of Ad in plasma in amounts as low as 2 ng/ml. Plasma Ad levels at 24 hours in rabbits and in patients both given a 1-mg/kg dose, previously regarded as difficult to be measured, are now easily measurable using as little as 0.5 ml of plasma. Multiple samples (ten to 15) can be analyzed by this method within a day.

Entities:  

Mesh:

Substances:

Year:  1976        PMID: 1035506

Source DB:  PubMed          Journal:  Cancer Treat Rep        ISSN: 0361-5960


  6 in total

1.  Influence of tumor on adriamycin concentration in blood cells.

Authors:  M Broggini; T Colombo; S Garattini; M G Donelli
Journal:  Cancer Chemother Pharmacol       Date:  1980       Impact factor: 3.333

Review 2.  Anthracycline antitumour agents. A review of physicochemical, analytical and stability properties.

Authors:  J Bouma; J H Beijnen; A Bult; W J Underberg
Journal:  Pharm Weekbl Sci       Date:  1986-04-25

3.  Differential adriamycin distribution to blood components.

Authors:  T Colombo; M Broggini; S Garattini; M G Donelli
Journal:  Eur J Drug Metab Pharmacokinet       Date:  1981       Impact factor: 2.441

4.  Time dependency of adriamycin and adriamycinol kinetics.

Authors:  P Gil; R Favre; A Durand; A Iliadis; J P Cano; Y Carcassonne
Journal:  Cancer Chemother Pharmacol       Date:  1983       Impact factor: 3.333

5.  [The pharmacokinetics of adriamycin and adriamycin-metabolites (author's transl)].

Authors:  G Ehninger; H J Stocker; B Proksch; K Wilms
Journal:  Klin Wochenschr       Date:  1980-09-15

6.  Phase I and pharmacologic study of liposomal daunorubicin (DaunoXome).

Authors:  P Guaglianone; K Chan; E DelaFlor-Weiss; R Hanisch; S Jeffers; D Sharma; F Muggia
Journal:  Invest New Drugs       Date:  1994       Impact factor: 3.850

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.